Abstract 20476: Ticagrelor : Similar Rates of Perioperative Hemorrhagic Complications and Mid-Term Survival Compared With Clopidogrel

Introduction: The PLATO trial suggested that ticagrelor is associated with better survival at 1 year for patients with acute coronary syndrome (ACS) undergoing coronary artery bypass grafting (CABG). The aim of this study was to compare perioperative bleeding complications and mid-term outcomes of patients receiving ticagrelor or clopidogrel perioperatively over a 2 years period in our institution. Hypothesis: We assessed the hypothesis that perioperative use of ticagrelor would result in better clinical outcomes without increasing bleeding risks in ACS patients undergoing CABG. Methods: Data were recorded from 467 patient’s file who underwent CABG following an ACS between 2013 and 2015. The Bleeding Academic Research Consortium (BARC) and Thrombolysis in Myocardial Infarction (TIMI) criteria were used to assess major bleedings. Results: Ticagrelor was stopped 4.5±0.50 days prior to surgery (5.8±0.29 days for clopidogrel ; p=0.06). BARC (6.2% vs 8.5% ; p=0.46) and TIMI (5.2% vs 7.3% ; p=0.43) major bleedi...